Transport, metabolism and elimination mechanisms of anti-HIV agents

Advanced Drug Delivery Reviews

Volumn 39, Issue 1-3, 1999, Pages 81-103

  Li, Xiaoling ^a   Chan, William K ^a  

^a UNIVERSITY OF THE PACIFIC   (United States)

Author keywords

Anti HIV; Cytochrome P450; Drug delivery; Drug interactions; Elimination; Mechanism; Metabolism; Transport

Indexed keywords

ABSORPTION; ANTIBIOTICS; DRUG INTERACTIONS; ENZYME INHIBITION; METABOLISM; PHARMACOKINETICS; VIRUSES;

BIOAVAILABILITY; HUMAN IMMUNODEFICIENCY VIRUS (HIV);

CONTROLLED DRUG DELIVERY;

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CYTOCHROME P450; DELAVIRDINE; DIDANOSINE; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

BLOOD BRAIN BARRIER; BLOOD CEREBROSPINAL FLUID BARRIER; BLOOD PLACENTA BARRIER; CELL MEMBRANE; CENTRAL NERVOUS SYSTEM; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PENETRATION; DRUG TARGETING; DRUG TRANSPORT; GASTROINTESTINAL MUCOSA; GASTROINTESTINAL TRACT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PERMEABILITY BARRIER; PRIORITY JOURNAL; REVIEW; SKIN;

EID: 0032871057     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(99)00021-6     Document Type: Article

References (225)

1. Kwong P.D., Wyatt R., Robinson J., Sweet R.W., Sodroski J., Hendrickson W.A. Structure of an HIV gp120 envelop glycoprotein in complex with the CD4 receptor and a neutralizing antibody. Nature. 393:1998;648-659.
2. Rizzuto C.D., Wyatt R., Hernandez-Ramos N., Sun Y., Kwong P.D., Hendrickson W.A., Sodroski J. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science. 280:1998;1949-1953.
3. Wyatt R., Kwong P.D., Desjardins E., Sweet R.W., Robinson J., Hendrickson W.A., Sodroski J.G. The antigenic structure of the HIV gp120 envelop glycoprotein. Nature. 393:1998;705-711.
4. Watson J.D., Gilman M., Witkowski J., Zoller M. Recombinant DNA. 1992;485-509 Scientific American, New York.
5. Hartman N.R., Yarchoan R., Pluda J.M., Thomas R.V., Marczyk K.S., Broder S., Johns D.G. Pharmacokinetics of 2′,3′-dideoxyadenosine and 2′,3′-dideoxyinosine in patients with severe human immunodeficiency virus infection. Clin. Pharmacol. Ther. 47:1990;647-654.
6. Hartman N.R., Yarchoan R., Pluda J.M., Thomas R.V., Wyvill K.M., Flora K.P., Broder S., Johns D.G. Pharmacokinetics of 2′,3′-dideoxyinosine in patients with severe human immunodeficiency infection. II. The effects of different oral formulations and the presence of other medications. Clin. Pharmacol. Ther. 50:1991;278-285.
7. Knupp C.A., Shyu W.C., Dolin R., Valentine F.T., McLaren C., Martin R.R., Pittman K.A., Barbhaiya R.H. Pharmacokinetics of didanosine in patients with acquired immunodeficiency syndrome or acquired immunodeficiency syndrome-related complex. Clin. Pharmacol. Ther. 49:1991;523-535.
8. Park G.B., Mitra A.K. Mechanism and site dependency of intestinal mucosal transport and metabolism of thymidine analogues. Pharm. Res. 9:1992;326-331.
9. Bramer S.L., Wientjes M.G., Au J.L. Absorption of 2′,3′-dideoxyinosine from lower gastrointestinal tract in rats and kinetic evidence of different absorption rates in colon and rectum. Pharm. Res. 10:1993;763-770.
10. Sinko P.J., Patel N.R., Hu P. Site-specific oral absorption of didanosine: in situ characterization and correlation with extent of absorption in vivo. Int. J. Pharm. 109:1994;125-133.
11. Sinko P.J., Hu P., Waclawski A.P., Patel N.R. Oral absorption of anti-AIDS nucleoside analogues. 1. Intestinal transport of didanosine in rat and rabbit preparations. J. Pharm. Sci. 84:1995;959-965.
12. Sinko P.J., Hu P. Determination intestinal metabolism and permeability for several compounds in rats. Implications on regional bioavailability in humans. Pharm. Res. 13:1996;108-113.
13. Sinko P.J., Sutyak J.P., Leesman G.D., Hu P., Makhey V.D., Yu H., Smith C.L. Oral absorption of anti-aids nucleoside analogues: 3. Regional absorption and in vivo permeability of 2′,3′-dideoxyinosine in an intestinal-vascular access port (IVAP) dog model. Biopharm. Drug Dispos. 18:1997;697-710.
14. Johnson D.A., Amidon G.L. Determination of intrinsic membrane transport parameters from perfused intestine experiments: a boundary layer approach to estimating the aqueous and unbiased membrane permeabilities. J. Theor. Biol. 131:1988;93-106.
15. Mirchandani H.L., Chien Y.W. Intestinal absorption of dideoxynucleosides: characterization using a multiloop in situ technique. J. Pharm. Sci. 84:1995;44-48.
16. Plagemann P.G., Wohlhueter R.M., Woffendin C. Nucleoside and nucleobase transport in animal cells. Biochim. Biophys. Acta. 947:1988;405-443.
17. Cornford E.M., Oldendorf W.H. Independent blood-brain barrier transport systems for nucleic acid precursors. Biochim Biophys Acta. 394:1975;211-219.
18. Young J.D., Jarvis S.M. Nucleoside transport in animal cells. Biosci. Rep. 3:1983;309-322.
19. Kalaria R.N., Harik S.I. Nucleoside transporter of cerebral microvessels and choroid plexus. J. Neurochem. 47:1986;1849-1856.
20. Waclawski A.P., Sinko P.J. Oral absorption of anti-acquired immune deficiency syndrome nucleoside analogues. 2. Carrier-mediated intestinal transport of stavudine in rat and rabbit preparations. J. Pharm. Sci. 85:1996;478-485.
21. Kwei G.Y., Novak L.B., Hettrick L.A., Reiss E.R., Ostovic D., Loper A.E., Lui C.Y., Higgins R.J., Chen I.W., Lin J.H. Regiospecific intestinal absorption of the HIV protease inhibitor L-735,524 in beagle dogs. Pharm. Res. 12:1995;884-888.
22. Lin J.H., Chen I.W., Vastag K.J., Ostovic D. pH-dependent oral absorption of L-735,524, a potent HIV protease inhibitor, in rats and dogs. Drug Metab. Dispos. 23:1995;730-735.
23. Kim R.B., Fromm M.F., Wandel C., Leake B., Wood A.J., Roden D.M., Wilkinson G.R. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin. Invest. 101:1998;289-294.
24. Wearley L., Chien Y.W. Enhancement of the in vitro skin permeability of azidothymidine (AZT) via iontophoresis and chemical enhancer. Pharm. Res. 7:1990;34-40.
25. Kim D.D., Chien Y.W. Transdermal delivery of zalcitabine: in vitro skin permeation study. AIDS. 9:1995;1331-1336.
26. Kim D.D., Chien Y.W. Transdermal delivery of dideoxynucleoside-type anti-HIV drugs. 1. Stability studies for hairless rat skin permeation. J. Pharm. Sci. 84:1995;1061-1066.
27. Kim D.D., Chien Y.W. Transdermal delivery of dideoxynucleoside-type anti-HIV drugs. 2. The effect of vehicle and enhancer on skin permeation. J. Pharm. Sci. 85:1996;214-219.
28. Kim D.D., Chien Y.W. Comparison of skin permeation of dideoxynucleoside-type anti-HIV drugs: alone versus combination. Drug Dev. Ind. Pharm. 22:1996;1047-1054.
29. Kim D.D., Chien Y.W. Simultaneous skin permeation of dideoxynucleoside-type anti-HIV drugs. J. Controlled Rel. 40:1996;67-76.
30. Kim D.D., Kim J.L., Chien Y.W. Mutual hairless rat skin permeation-enhancing effect of ethanol/water system and oleic acid. J. Pharm. Sci. 85:1996;1191-1195.
31. Corbo D.C., Liu J.C., Chien Y.W. Characterization of the barrier properties of mucosal membranes. J. Pharm. Sci. 79:1990;202-206.
32. Seki T., Sato N., Hasegawa T., Kawaguchi T., Juni K. Nasal absorption of zidovudine and its transport to cerebrospinal fluid in rats. Biol. Pharm. Bull. 17:1994;1135-1137.
33. Yajima T., Hasegawa T., Juni K., Saneyoshi M., Kawaguchi T. Nasal absorption of 2′,3′-didehydro-3′-deoxythymidine (D4T) and its esters in rats. Biol. Pharm. Bull. 19:1996;1234-1237.
34. Yajima T., Juni K., Saneyoshi M., Hasegawa T., Kawaguchi T. Direct transport of 2′,3′-didehydro-3′-deoxythymidine (D4T) and its ester derivatives to the cerebrospinal fluid via the nasal mucous membrane in rats. Biol. Pharm. Bull. 21:1998;272-277.
35. Gandhi R.B., Robinson J.R. Oral cavity as a site for bioadhesive drug delivery. Adv. Drug Delivery Rev. 13:1994;43-74.
36. Squier C.A., Hopps R.M. A study of the permeability barrier in epidermis and oral epithelium using horseradish peroxidase as a tracer in vitro. Br. J. Dermatology. 95:1976;123-129.
37. Squier C.A. Membrane coating granules in nonkeratinizing oral epithelium. J. Ultrastructure Res. 60:1977;212-220.
38. Xiang J., Shen S.I., Li X. Transbuccal delivery of 2′,3′-dideoxycytidine: in vitro permeation studies. Pharm. Sci. 1:1998;S-430.
39. Shojaei A.H., Berner B., Li X. Transbuccal delivery of acyclovir (I): In vitro determination of routes of buccal transport. Pharm. Res. 15:1998;1182-1188.
40. Lipton S.A. Neuronal injury associated with HIV-1: approaches to treatment. Ann. Rev. Pharmacol. Toxicol. 38:1998;159-177.
41. Gallo J.M. Delivery of anti-HIV nucleosides to the central nervous system. Adv. Drug Delivery Rev. 14:1994;199-209.
42. Thomas S.A., Segal M.B. The passage of azidodeoxythymidine into and within the central nervous system: does it follow the parent compound, thymidine? J. Pharmacol. Exp. Ther. 281:1997;1211-1218.
43. Masereeuw R., Jaehde U., Langemeijer M.W., de Boer A.G., Breimer D.D. In vitro and in vivo transport of zidovudine (AZT) across the blood-brain barrier and the effect of transport inhibitors. Pharm. Res. 11:1994;324-330.
44. Hoesterey B.L., Galinsky R.E., Anderson B.D. Dose dependence in the plasma pharmacokinetics and uptake kinetics of 2′,3′-dideoxyinosine into brain and cerebrospinal fluid of rats. Drug Metab. Dispos. 19:1991;907-912.
45. Yang Z., Brundage R.C., Barbhaiya R.H., Sawchuk R.J. Microdialysis studies of the distribution of stavudine into the central nervous system in the freely-moving rat. Pharm. Res. 14:1997;865-872.
46. Collins J.M., Klecker R.W. Jr., Kelley J.A., Roth J.S., McCully C.L., Balis F.M., Poplack D.G. Pyrimidine dideoxyribonucleosides: selectivity of penetration into cerebrospinal fluid. J. Pharmacol. Exp. Ther. 245:1988;466-470.
47. Spector R. Drug transport in the central nervous system: role of carriers. Pharmacology. 40:1990;1-7.
48. R.E. Galinsky, B.L. Hoesterey, B.D. Anderson, Brain and cerebrospinal fluid uptake of zidovudine (AZT) in rats after intravenous injection [published erratum appears in Life. Sci. 47(23) (1990) 171]. Life Sci. 47 (1990) 781-788.
49. R.E. Galinsky, B.L. Hoesterey, B.D. Anderson, Brain and cerebrospinal fluid uptake of zidovudine (AZT) in rats after intravenous injection [published erratum appears in Life. Sci. 47(23) (1990) 171]. Life Sci. 47 (1990) 781-788.
50. Ahmed A.E., Jacob S., Loh J.P., Samra S.K., Nokta M., Pollard R.B. Comparative disposition and whole-body autoradiographic distribution of [2-14C]azidothymidine and [2-14C]thymidine in mice. J. Pharmacol. Exp. Ther. 257:1991;479-486.
51. Terasaki T., Pardridge W.M. Restricted transport of 3′-azido-3′-deoxythymidine and dideoxynucleosides through the blood-brain barrier. J. Infect. Dis. 158:1988;630-632.
52. Wong S.L., Wang Y., Sawchuk R.J. Analysis of zidovudine distribution to specific regions in rabbit brain using microdialysis. Pharm. Res. 9:1992;332-338.
53. Galinsky R.E., Flaharty K.K., Hoesterey B.L., Anderson B.D. Probenecid enhances central nervous system uptake of 2′,3′-dideoxyinosine by inhibiting cerebrospinal fluid efflux. J. Pharmacol. Exp. Ther. 257:1991;972-978.
54. Takasawa K., Terasaki T., Suzuki H., Sugiyama Y. In vivo evidence for carrier-mediated efflux transport of 3′-azido-3′-deoxythymidine and 2′,3′-dideoxyinosine across the blood-brain barrier via a probenecid-sensitive transport system. J. Pharmacol. Exp. Ther. 281:1997;369-375.
55. Tuntland T., Ravasco R.J., al H.S., Unadkat J.D. Efflux of zidovudine and 2′,3′-dideoxyinosine out of the cerebrospinal fluid when administered alone and in combination to Macaca nemestrina. Pharm. Res. 11:1994;312-317.
56. Takasawa K., Terasaki T., Suzuki H., Ooie T., Sugiyama Y. Distributed model analysis of 3′-azido-3′-deoxythymidine and 2′,3′-dideoxyinosine distribution in brain tissue and cerebrospinal fluid. J. Pharmacol. Exp. Ther. 282:1997;1509-1517.
57. Wang Y., Sawchuk R.J. Zidovudine transport in the rabbit brain during intravenous and intracerebroventricular infusion. J. Pharm. Sci. 84:1995;871-876.
58. Wong S.L., Van B.K., Sawchuk R.J. Distributional transport kinetics of zidovudine between plasma and brain extracellular fluid/cerebrospinal fluid in the rabbit: investigation of the inhibitory effect of probenecid utilizing microdialysis. J. Pharmacol. Exp. Ther. 264:1993;899-909.
59. Glynn S.L., Yazdanian M. In vitro blood-brain barrier permeability of nevirapine compared to other HIV antiretroviral agents. J Pharm Sci. 87:1998;306-310.
60. Johnson M.D., Anderson B.D. Localization of purine metabolizing enzymes in bovine brain microvessel endothelial cells: an enzymatic blood-brain barrier for dideoxynucleosides? Pharm. Res. 13:1996;1881-1886.
61. Bawdon R.E., Sobhi S., Dax J. The transfer of anti-human immunodeficiency virus nucleoside compounds by the term human placenta. Am. J. Obstet. Gynecol. 167:1992;1570-1574.
62. Tuntland T., Nosbisch C., Baughman W.L., Massarella J., Unadkat J.D. Mechanism and rate of placental transfer of zalcitabine (2′,3′-dideoxycytidine) in Macaca nemestrina. Am. J. Obstet. Gynecol. 174:1996;856-863.
63. Sandberg J.A., Binienda Z., Lipe G., Rose L.M., Parker W.B., Ali S.F., Slikker W.J. Placental transfer and fetal disposition of 2′,3′-dideoxycytidine and 2′,3′-dideoxyinosine in the rhesus monkey. Drug Metab. Dispos. 23:1995;881-884.
64. Henderson G.I., Perez A.B., Yang Y., Hamby R.L., Schenken R.S., Schenker S. Transfer of dideoxyinosine across the human isolated placenta. Br. J. Clin. Pharmacol. 38:1994;237-242.
65. Bloom S.L., Dias K.M., Bawdon R.E., Gilstrap L.r. The maternal-fetal transfer of lamivudine in the ex vivo human placenta. Am. J. Obstet. Gynecol. 176:1997;291-293.
66. Bawdon R.E., Kaul S., Sobhi S. The ex vivo transfer of the anti-HIV nucleoside compound d4T in the human placenta. Gynecol. Obstet. Invest. 38:1994;1-4.
67. Odinecs A., Nosbisch C., Unadkat J.D. Zidovudine does not affect transplacental transfer or systemic clearance of stavudine (2′,3′-didehydro-3′-deoxythymidine) in the pigtailed macaque (Macaca nemestrina). Antimicrob. Agents Chemother. 40:1996;1569-1571.
68. Zimmerman T.P., Mahony W.B., Prus K.L. 3′-azido-3′-deoxythymidine. An unusual nucleoside analogue that permeates the membrane of human erythrocytes and lymphocytes by nonfacilitated diffusion. J. Biol. Chem. 262:1987;5748-5754.
69. Zimmerman T.P., Prus K.L., Mahony W.B., Domin B.A. 3′-azido-3′-deoxythymidine and acyclovir: antiviral nucleoside analogues with unusual cell membrane permeation properties. Adv. Exp. Med. Biol. 253B:1989;399-406.
70. Domin B.A., Mahony W.B., Zimmerman T.P. 2′,3′-Dideoxythymidine permeation of the human erythrocyte membrane by nonfacilitated diffusion. Biochem. Biophys. Res. Commun. 154:1988;825-831.
71. Magnani M., Bianchi M., Rossi L., Stocchi V. 2′,3′-dideoxycytidine permeation of the human erythrocyte membrane. Biochem. Int. 19:1989;227-234.
72. Domin B.A., Mahony W.B., Zimmerman T.P. Membrane permeation mechanisms of 2′,3′-dideoxynucleosides. Biochem. Pharmacol. 46:1993;725-729.
73. August E.M., Birks E.M., Prusoff W.H. 3′-Deoxythymidin-2′-ene permeation of human lymphocyte H9 cells by nonfacilitated diffusion. Mol. Pharmacol. 39:1991;246-249.
74. Chan T.C., Shaffer L., Redmond R., Pennington K.L. Permeation and metabolism of anti-HIV and endogenous nucleosides in human immune effector cells. Biochem. Pharmacol. 46:1993;273-278.
75. Hu M. Comparison of uptake characteristics of thymidine and zidovudine in a human intestinal epithelial model system. J. Pharm. Sci. 82:1993;829-833.
76. Yusa K., Oh-hara T., Yamazaki A., Tsukahara S., Satoh W., Tsuruo T. Cross-resistance to anti-HIV nucleoside analogs in multidrug-resistant cancer cells. Biochem. Biophys. Res. Commun. 169:1990;986-990.
77. Lee C.G., Gottesman M.M., Cardarelli C.O., Ramachandra M., Jeang K.T., Ambudkar S.V., Pastan I., Dey S. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry. 37:1998;3594-3601.
78. Bourdais J., Biondi R., Sarfati S., Guerreiro C., Lascu I., Janin J., Veron M. Cellular phosphorylation of anti-HIV nucleosides: role of nucleoside diphosphate kinase. J. Biol. Chem. 271:1996;7887-7890.
79. Furman P.A., Fyfe J.A., St. Clair M.H., Weinhold K., Rideout J.L., Freeman G.A., Lehrman S.N., Bolognesi D.P., Broder S., Mitsuya H. Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-phosphate with human immunodeficiency virus reverse transcriptase. Proc. Natl. Acad. Sci. USA. 83:1986;8333-8337.
80. Balzarini J., Herdewijn P., Clercq E. Differential patterns of intracellular metabolism of 2′,3′-dideoxythymidine and 3′-azido-2′,3′-dideoxythymidine, two potent anti-human immunodeficiency virus compounds. J. Biol. Chem. 264:1989;6127-6133.
81. Xu Y., Sellam O., Morera S., Sarfati S., Biondi R., Veron M., Janin J. X-ray analysis of azido-thymidine diphosphate binding to nucleoside diphosphate kinase. Proc. Natl. Acad. Sci. USA. 94:1997;7162-7165.
82. Dudley M.N. Clinical pharmacokinetics of nucleoside antiretroviral agents. J. Infect. Dis. 171:1995;S99-S112.
83. Blum M.R., Liao S.H., Good S.S., de Miranda P. Pharmacokinetics and bioavailability of zidovudine in humans. Am. J. Med. 85:1988;189-194.
84. De Miranda P., Good S.S., Yarchoan R., Thomas R.V., Blum M.R., Myers C.E., Broder S. Alteration of zidovudine pharmacokinetics by probenecid in patients with AIDS or AIDS-related complex. Clin. Pharmacol. Ther. 46:1989;494-500.
85. Morse G.D., Portmore A.C., Marder V.C.P., Olson J., Taylor C., Bonnez W., Reichman R.C. Intravenous and oral zidovudine pharmacokinetics and coagulation effects in asymptomatic human immunodeficiency virus-infected hemophilia patients. Antimicrob. Agents Chemother. 36:1992;2245-2252.
86. Fischer P.H., Lin T.S., Prusoff W.H. Reversal of the cytotoxicity of 3′-amino-3′-deoxythymidine by pyrimidine deoxyribonucleosides. Biochem. Pharmacol. 28:1979;991-994.
87. Lin T.S., Fischer P.H., Prusoff W.H. Effect of 3′-amino-3′-deoxythymidine on L1210 and P388 leukemias in mice. Biochem. Pharmacol. 31:1982;125-128.
88. Stagg M.P., Cretton E.M., Kidd L., Diasio R.B., Sommadossi J.P. Clinical pharmacokinetics of 3′-azido-3′-deoxythymidine (zidovudine) and catabolites with the formation of a toxic catabolite, 3′-amino-3′-deoxythymidine. Clin. Pharmacol. Ther. 51:1992;668-676.
89. Chen M.S., Woods K.L., Prusoff W.H. Molecular basis of the antineoplastic activity of 3′-amino-3′-deoxythymidine. Mol. Pharmacol. 25:1984;441-445.
90. Eagling V.A., Howe J.L., Barry M.J., Back D.J. The metabolism of zidovudine by human liver microsomes in vitro: formation of 3′-amino-3′-deoxythymidine. Biochem. Pharmacol. 48:1994;267-276.
91. Pan-Zhou X.-R., Cretton-Scott E., Zhou X.-J., Yang M.-X., Lasker J.M., Sommadossi J.-P. Role of human liver P450s and cytochrome b5 in the reductive metabolism of 3′-amino-3′-deoxythymidine. Biochem. Pharmacol. 55:1998;757-766.
92. Larder B.A., Kemp S.D. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science. 246:1989;1155-1158.
93. Larder B.A., Kellman P., Kemp S.D. Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes. AIDS. 5:1991;137-144.
94. Kellam P., Boucher C.A., Larder B.A. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc. Natl. Acad. Sci. USA. 89:1992;1934-1938.
95. Larder B.A. Interactions between drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase. J. Gen. Virol. 75:1994;951-957.
96. Kerr S.G., Anderson K.S. Pre-steady-state kinetic characterization of wild type and 3′-azido-3′-deoxythymidine (AZT) resistant human immunodeficiency virus type 1 reverse transcriptase: implication of RNA directed DNA polymerization in the mechanism of AZT resistance. Biochemistry. 36:1997;14064-14070.
97. Antonelli G., Turriziani O., Cianfriglia M., Riva E., Dong G., Fattorossi A., Dianzani F. Resistance of HIV-1 to AZT might also involve the cellular expression of multidrug resistance P-glycoprotein. AIDS Res. Hum. Retroviruses. 8:1992;1839-1844.
98. Nyce J., Leonard S., Canupp D., Schulz S., Wong S. Epigenetic mechanisms of drug resistance: drug-induced DNA hypermethylation and drug resistance. Proc. Natl. Acad. Sci. USA. 90:1993;2960-2964.
99. Wu S., Liu X., Solorzano M.M., Kwock R., Avramis V.I. Development of zidovudine (AZT) resistance in Jurkat T cells is associated with decreased expression of the thymidine kinase (TK) gene and hypermethylation okf the 5′ end of human TK gene. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 8:1995;1-9.
100. Lucarelli M., Palitti F., Carotti D., Cianfriglia M., Signoretti C., Bozzi A., Strom R. AZT-induced hypermethylation of human thymidine kinase gene in the absence of total DNA hypermethylation. FEBS Lett. 396:1996;323-326.
101. De Vito M., Bozzi A., Ferretti A., Cianfriglia M., Barca S., Signoretti C., Lenti L., d'Agostino F., Strom R., Podo F. Intracellular metabolism of 3′-azido-3′-deoxythymidine (AZT): a nuclear magnetic resonance study on T-lymphoblast cell lines with different resistance to AZT. Biochem. Pharmacol. 54:1997;979-990.
102. Mazumder A., Cooney D., Agbaria R., Gupta M., Pommier Y. Inhibition of human immunodeficiency virus type 1 integrase by 3′-azido-3′-deoxythymidylate. Proc. Natl. Acad. Sci. USA. 91:1994;5771-5775.
103. Chow H.H., Brookshier G., Li P. Tissue disposition of zidovudine and its phosphorylated metabolites in zidovudine-treated healthy and retrovirus infected mice. Pharm. Res. 15:1998;139-144.
104. Gao W.Y., Shirasaka T., Johns D.G., Broder S., Mitsuya H. Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells. J. Clin. Invest. 91:1993;2326-2333.
105. Perry C.M., Balfour J.A. Didanosine. An update on its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV disease. Drugs. 52:1996;928-962.
106. Johnson M.A., Fridland A. Phosphorylation of 2′,3′-dideoxyinosine by cytosolic 5′-nucleotidase of human lymphoid cells. Mol. Pharmacol. 36:1989;291-295.
107. Johnson M.A., Ahluwalia G., Conndelly M.C., Cooney D.A., Broder S., Johns D.G., Fridland A. Metabolic pathways for the activation of the antiretroviral agent 2′,3′-dideoxyadenosine in human lymphoid cells. J. Biol. Chem. 263:1988;15354-15357.
108. Chen C.H., Vasquez-Padua M., Cheng Y.C. Effect of anti-human immunodeficiency virus nucleoside analogs on mitochondrial DNA and its implication for delayed toxicity. Mol. Pharmacol. 39:1991;625-628.
109. Ahluwalia G., Cooney D.A., Mitsuya H., Fridland A., Flora K.P., Hao Z., Dalal M., Broder S., Johns D.G. Initial studies on the cellular pharmacology of 2′,3′-dideoxyinosine, an inhibitor of HIV infectivity. Biochem. Pharmacol. 36:1987;3797-3800.
110. Morse G.D., Shelton M.J., O'Donnell A.M. Comparative pharmacokinetics of antiviral nucleoside analogues. Clin. Pharmacokinet. 24:1993;101-123.
111. Drusano G.L., Yuen G.J., Morse G., Cooley T.P., Seidlin M., Lambert J.S., Liebman H.A., Valentine F.T., Dolin R. Impact of bioavailability on determination of the maximal tolerated dose of 2′,3′-dideoxyinosine in phase I trials. Antimicrob. Agents Chemother. 36:1992;1280-1283.
112. Didanosine (Videx) Product Information, Bristol Myers-Squibb, Princeton, NJ, 1996.
113. Bruzzese V.L., Gillum J.G., Israel D.S., Johnson G.L., Kaplowitz L.G., Polk R.E. Effect of fluconazole on pharmacokinetics of 2′,3′-dideoxyinosine in persons seropositive for human immunodeficiency virus. Antimicrob. Agents Chemother. 39:1995;1050-1053.
114. Starnes M.C., Cheng Y.C. Cellular metabolism of 2′,3′-dideoxycytidine, a compound active against human immunodeficiency virus in vitro. J. Biol. Chem. 262:1987;988-991.
115. Broder S. Pharmacodynamics of 2′,3′-dideoxycytidine: an inhibitor of human immunodeficiency virus. Am. J. Med. 88:1990;2S-7S.
116. Cooney D.A., Dalal M., Mitsuya H., McMahon J.B., Nadkarni M., Nalzarini J., Broder S., Johns D.G. Initial studies on the cellular pharmacology of 2′,3′-dideoxycytidine, an inhibitor of HTL-III infectivity. Biochem. Pharmacol. 35:1986;2065-2068.
117. Balzarini J., Cooney D.A., Dalal M., Kang G.J., Cupp J.E., DeClercq E., Broder S., Johns D.G. 2′,3′-dideoxycytidine: regulation of its metabolism and anti-viral potency by natural pyrimidine nucleosides and by inhibition of pyrimidine nucleotide synthesis. Mol. Pharmacol. 32:1987;798-806.
118. Gustavson L.E., Fukuda E.K., Rubio F.A., Dunton A.W. A pilot study of the bioavailability and pharmacokinetics of 2′,3′-dideoxycytidine in patients with AIDS or AIDS-related complex. J. Acquir. Immune Defic. Syndr. 3:1990;28-31.
119. Klecker R.J., Collins J.M., Yarchoan R.C., Thomas R., McAtee N., Broder S., Myers C.E. Pharmacokinetics of 2′,3′-dideoxycytidine in patients with AIDS and related disorders. J. Clin. Pharmacol. 28:1988;837-842.
120. Zalcitabine (Hivid) Product Information, Roche Lab, Nutley, NJ, 1996.
121. Lin T.-S., Schinazi R.F., Prusoff W.H. Potent and selective in vitro activity of 3′-deoxythymidin-2′-ene (3′deoxy-2′,3′-didehydrothymidine) against human immunodeficiency virus. Biochem. Pharmacol. 36:1987;2713-2718.
122. Ahluwalia G.S., Gao W.-Y., Mitsuya H., Johns D.G. 2′,3′-Didehydro-3′-deoxythymidine: regulation of its metabolic activation by modulators of thymidine-5′-phosphate biosynthesis. Mol. Pharmacol. 50:1996;160-165.
123. Shewach D.S., Liotta D.C., Schinazi R.F. Affinity of the antiviral enantiomers of oxathiolane cytosine nucleosides for human 2′-deoxycytidine kinase. Biochem. Pharmacol. 45:1993;1540-1543.
124. Cammack N., Rouse P., Marr C.L., Reid P.J., Boehme R.E., Coates J.A., Penn C.R., Cameron J.M. Cellular metabolism of (-) enantiomeric 2′-deoxy-3′-thiacytidine. Biochem. Pharmacol. 43:1992;2059-2064.
125. Perry C.M., Faulds D. Lamivudine. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection. Drugs. 53:1997;657-680.
126. Barry M., Howe J.L., Ormesher S., Back D.J., Breckenridge A.M., Bergin C., Mulcahy F., Beeching N., Nye F. Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in patients with the acquired immunodeficiency syndrome. Br. J. Clin. Pharmacol. 37:1994;421-426.
127. Gibb D., Barry M., Ormesher S., Nokes L., Seefried M., Giaquinto C., Back D. Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in children with HIV infection. Br. J. Clin. Pharmacol. 39:1995;527-530.
128. Hardman J.G., Limbird L.E. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 1996;1191-1223 McGraw-Hill, New York.
129. Shih C.-K., Rose J.M., Hansen G.L., Wu J.C., Bacolla A., Griffin J.A. Chimeric human immunodeficiency virus type-1/type-2 reverse transcriptases display reversed sensitivity to nonnucleoside analog inhibitors. Proc. Natl. Acad. Sci. USA. 88:1991;9878-9882.
130. Nunberg J.H., Schleif W.A., Boots E.J., O'Brien J.A., Quintero J.C., Hoffman J.M. Viral resistance to human immunodeficiency virus type-1 specific pyridinone reverse transcriptase inhibitors. J. Virol. 65:1991;4887-4892.
131. Richman D., Shih C.-K., Lowy I., Rose J., Prodanovich P., Goff S. Human immunodeficiency virus type-1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture. Proc. Natl. Acad. Sci. USA. 88:1991;11241-11245.
132. Beach J.W. Chemotherapeutic agents for human immunodeficiency virus infection: mechanism of action, pharmacokinetics, metabolism, and adverse reactions. Clin. Ther. 20:1998;2-25.
133. Cheeseman S.H., Hattox S.E., McLaughlin M.M., Koup R.A., Andrews C., Bova C.A., Pav J.W., Roy T., Sullivan J.L., Keirns J.J. Pharmacokinetics of nevirapine: initial single-rising-dose study in humans. Antimicrob. Agents Chemother. 37:1993;178-182.
134. Rosser L.M., O'Donnell A.M., Lee K.M., Morse G.D. In vitro protein-binding characteristics of atevirdine and its N-dealkylated metabolite. Antiviral Res. 25:1994;193-200.
135. Been-Tiktak A.M.M., Vrehen H.M., Schneider M.M.E., van der Feltz M., Branger T., Ward P., Cox S.R., Harry J.D., Borleffs J.C.C. Safety, tolerance, and pharmacokinetics of atevirdine mesylate (U-87201E) in asymptomatic human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 39:1995;602-607.
136. Chang M., Sood V.K., Wilson G.J., Kloosterman D.A., Sanders P.E., Hauer M.J., Fagerness P.E. Metabolism of the human immunodeficiency virus type 1 reverse transcriptase inhibitor delavirdine in rats. Drug Metab. Dispos. 25:1997;228-242.
137. Chang M., Sood V.K., Kloosterman D.A., Hauer M.J., Fagerness P.E., Sanders P.E., Vrbanac J.J. Identification of the metabolites of the HIV-1 reverse transcriptase inhibitor delavirdine in monkeys. Drug Metab. Dispos. 25:1997;814-827.
138. Freimeth W.W. Delavirdine Mesylate, A Potent Non-nucleoside HIV-1 Reverse Transcriptase Inhibitor. 1996;279-289 Plenum Press, New York and London.
139. Moyle G., Gazzard B. Current knowledge and future prospects for the use of HIV protease inhibitors. Drugs. 51:1996;701-712.
140. Kempf D.J., Marsh K.C., Denissen J.F., McDonald E., Vasavanonda S., Flentge C.A., Green B.E., Fino L., Park C.H., Kong X.P., et al. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc. Natl. Acad. Sci. USA. 92:1995;2484-2488.
141. Lea A.P., Faulds D. Ritonavir. Drugs. 52:1996;541-546.
142. Fitzsimmons M.E., Collins J.M. Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P4503A4: potential contribution to high first-pass metabolism. Drug Metab. Dispos. 25:1997;256-266.
143. Vacca J.P., Dorsey B.D., Schleif W.A., Levin R.B., McDaniel S.L., Darke P.L., Zugay J., Quintero J.C., Blahy O.M., Roth E., et al. L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proc. Natl. Acad. Sci. USA. 91:1994;4096-4100.
144. Lin J.H., Chiba M., Balani S.K., Chen I.W., Kwei G.Y., Vastag K.J., Nishime J.A. Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immunodeficiency virus protease inhibitor. Drug Metab. Dispos. 24:1996;1111-1120.
145. Chiba M., Hensleigh M., Nishime J.A., Balani S.K., Lin J.H. Role of cytochrome P450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor. Drug Metab. Dispos. 24:1996;307-314.
146. Chiba M., Hensleigh M., Lin J.H. Hepatic and intestinal metabolism of indinavir, an HIV protease inhibitor, in rat and human microsomes. Biochem. Pharmacol. 53:1997;1187-1195.
147. Balani S.K., Arison B.H., Mathai L., Kauffman L.R., Miller R.R., Stearns R.A. Metabolites of L-735,524, a potent HIV-1 protease inhibitor, in human urine. Drug Metab. Dispos. 23:1995;266-270.
148. Lin J.H., Chiba M., Chen I.W., Nishime J.A., Vastag K.J. Sex-dependent pharmacokinetics of indinavir: in vivo and in vitro evidence. Drug Metab. Dispos. 24:1996;1298-1306.
149. Kumar G.N., Rodrigues A.D., Buko A.M., Denissen J.F. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J. Pharmacol. Exp. Ther. 277:1996;423-431.
150. Jarvis B., Faulds D. Nelfinavir: a review of its therapeutic efficacy in HIV infection. Drugs. 56:1998;147-167.
151. Lillibridge J.H., Liang B.H., Kerr B.M., Webber S., Quart B., Shetty B.V., Lee C.A. Characterization of the selectivity and mechanism of human cytochrome P450 inhibition by the human immunodeficiency virus-protease inhibitor nelfinavir mesylate. Drug Metab. Dispos. 26:1998;609-616.
152. von Moltke L.L., Greenblatt D.J., Grassi J.M., Granda B.W., Duan S.X., Fogelman S.M., Daily J.P., Harmatz J.S., Shader R.I. Protease inhibitors as inhibitors of human cytochrome P450: high risk associated with ritonavir. J. Clin. Pharmacol. 38:1998;106-111.
153. Saquinavir (Invirase), Roche Lab, Nutley, NJ, 1997.
154. Merry C., Barry M.G., Mulcahy F., Ryan M., Heavey J., Tija J.F., Gibbons S.E., Breckenridge A.M., Back D.J. Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. AIDS. 11:1997;F29-F33.
155. Witzke O., Plentz A., Schafers R.F., Reinhardt W., Heemann U., Philipp T. Side-effects of ritonavir and its combination with saquinavir with special regard to renal function. AIDS. 11:1997;836-838.
156. Hsu A., Granneman G.R., Cao G., Carothers L., et-Shourbagy T., Baroldi P., Erdman K., Brown F., Sun E., Leonard J.M. Pharmacokinetic interactions between two human immunodeficiency virus inhibitors, ritonavir and saquinavir. Clin. Pharmacol. Ther. 63:1998;453-464.
157. Kempf D.J., Marsh K.C., Kumar G., Rodriques A.D., Denissen J.F., McDonald E., Kukulka M.J., Hsu A., Granneman G.R., Baroldi P.A., Sun E., Pizzuti D., Plattner J.J., Norbeck D.W., Leonard J.M. Pharmacokinetic enhancement of inhibitors of the human immune deficiency virus protease by coadministration with ritonavir. Antimicrob. Agents Chemother. 41:1997;654-660.
158. Merry C., Barry M.G., Mulcahy F., Halifax K.L., Back D.J. Saquinavir pharmacokinetics alone and in combination with nelfinavir in HIV-infected patients. AIDS. 11:1997;F117-F120.
159. Ferry J.J., Herman B.D., Carel B.J., Carlson G.F., Batts D.H. Pharmacokinetic drug-drug interaction study of delavirdine and indinavir in healthy volunteers. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 18:1998;252-259.
160. Kupferschmidt H.H., Fattinger K.E., Ha H.R., Follath F., Krahenbuhl S. Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man. Br. J. Clin. Pharmacol. 45:1998;355-359.
161. Edwards D.J., Bellevue F.H., Woster P.M. Identification of 6′-7′-dihydroxybergamottin, a cytochrome P450 inhibitor, in grapefruit juice. Drug Metab. Dispos. 24:1996;1287-1290.
162. He K., Iyer K.R., Hayes R.N., Sinz M.W., Woolf T.F., Hollenberg P.F. Inactivation of cytochrome P450 3A4 by bergamottin, a component of grapefruit juice. Chem. Res. Toxicol. 11:1998;252-259.
163. Fukuda K., Ohta T., Oshima Y., Ohashi N., Yoshikawa M., Yamazoe Y. Specific CYP3A4 inhibitors in grapefruit juice: furocoumarin dimers as components of drug interaction. Pharmacogenetics. 7:1997;391-396.
164. Fukuda K., Ohta T., Yamazoe Y. Grapefruit component interacting with rat and human P450 CYP3A: possible involvement of non-flavonoid components in drug interaction. Biol. Pharm. Bull. 20:1997;560-564.
165. Ducharme M.P., Warbasse L.H., Edwards D.J. Disposition of intravenous and oral cyclosporin after administration with grapefruit juice. Clin. Pharmacol. Ther. 57:1995;485-491.
166. Benton R.E., Honig P.K., Zamani K., Cantilena L.R., Woosley R.L. Grapefruit juice alters terfenadine pharmacokinetics, resulting in prolongation of repolarization on the electrocardiogram. Clin. Pharmacol. Ther. 59:1996;383-388.
167. Bailey D.G., Spence J.D., Munoz C., Arnold J.M.O. Interaction of citrus juices with felopidine and nifedipine. Lancet. 337:1991;268-269.
168. Edgar B., Bailey D., Bergstrand R., Johnsson G., Regardh C.G. Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine-and its potential clinical relevance. Eur. J. Clin. Pharmacol. 42:1992;313-317.
169. Ozdemir M., Aktan Y., Boydag B.S., Cingi M.I., Musmul A. Interaction between grapefruit juice and diazepam in humans. Eur. J. Drug Metab. Pharmacokinet. 23:1998;55-59.
170. Hukkinen S.K., Varhe A., Olkkola K.T., Neuvonen P.J. Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice. Clin. Pharmacol. Ther. 58:1995;127-131.
171. Kupferschmidt H.H.T., Ha H.R., Ziegler W.H., Meier P.J., Krahenbuhl S. Interaction between grapefruit juice and midazolam in humans. Clin. Pharmacol. Ther. 58:1995;20-28.
172. Kantola T., Kivisto K.T., Neuvonen P.J. Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. Clin. Pharmacol. Ther. 63:1998;397-402.
173. Lown K.S., Bailey D.G., Fontana R.J., Janardan S.K., Adair C.H., Fortlage L.A., Brown M.B., Guo W., Watkins P.B. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J. Clin. Invest. 99:1997;2545-2553.
174. Schmiedlin-Ren P., Edwards D.J., Fitzsimmons M.E., He K., Lown K.S., Woster P.M., Rahman A., Thummel K.E., Fisher J.M., Hollenberg P.F., Watkins P.B. Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents: decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins. Drug Metab. Dispos. 25:1997;1228-1233.
175. Lundahl J., Regardh C.G., Edgar B., Johnsson G. Relationship between time of intake of grapefruit juice and its effect on pharmacokinetics and pharmacodynamics of felodipine in healthy subjects. Eur. J. Clin. Pharmacol. 49:1995;61-67.
176. Chan W.K., Nguyen L.T., Miller V.P., Harris R.Z. Mechanism-based inactivation of human cytochrome P450 3A4 by grapefruit juice and red wine. Life Sci. 62:1998;PL135-PL142.
177. Ritonavir (Norvir) Product Information, Abbot Lab, N. Chicago, IL, 1997.
178. Merry C., Barry M.G., Mulcahy F., Ryan M., Tjia J.F., Halifax K.L., Breckenridge A.M., Back D.J. The pharmacokinetics of combination therapy with nelfinavir plus nevirapine. AIDS. 12:1998;1163-1167.
179. Skowron G., Leoung G., Kerr B., Dusek A., Anderson R., Beebe S., Grosso R. Lack of pharmacokinetic interaction between nelfinavir and nevirapine. AIDS. 12:1998;1243-1244.
180. Mirchandani H., Chien Y.W. Drug delivery approaches for anti-HIV drugs. Int. J. Pharm. 95:1993;1-21.
181. Mukherji E., Millenbaugh N.J., Au J.L. Percutaneous absorption of 2′,3′-dideoxyinosine in rats. Pharm. Res. 11:1994;809-815.
182. Kararli T.T., Kirchhoff C.F., Penzotti S.C. Enhancement of transdermal transport of azidothymidine (AZT) with novel terpene and terpene-like enhancers: in vivo-in vitro correlations. J Controlled Rel. 34:1995;43-51.
183. Seki T., Kawaguchi T., Sugibayashi K., Juni K., Morimoto Y. Percutaneous absorption of azidothymine in rats. Int. J. Pharm. 57:1989;73-75.
184. Seki T., Toeda C., Kawaguchi T., Juni K., Sugibayashi K., Morimoto Y. Enhanced transdermal delivery of zidovudine in rats and human skin. Chem. Pharm. Bull. 38:1990;3086-3089.
185. Seki T., Kawaguchi T., Juni K. Enhanced delivery of zidovudine through rat and human skin via ester prodrugs. Pharm. Res. 7:1990;948-952.
186. Kawaguchi T., Hasegawa T., Juni K., Seki T. Rectal absorption of zidovudine. Int. J. Pharm. 77:1991;71-74.
187. Gao X., Wientjes M.G., Au J.L. Extensive absorption of 2′,3′-dideoxyinosine by intratracheal administration in rats. Pharm Res. 12:1995;1901-1906.
188. Knupp C.A., Shyu W.C., Morgenthien E.A., Lee J.S., Barbhaiya R.H. Biopharmaceutics of didanosine in humans and in a model for acid-labile drugs, the pentagastrin-pretreated dog. Pharm. Res. 10:1993;1157-1164.
189. Anderson B.D., Wygant M.B., Xiang T.X., Waugh W.A., Stella V.J. Preformulation solubility and kinetic studies of 2′,3′-dideoxypurine nucleosides: potential anti-AIDS agents. Int. J. Pharm. 45:1988;27-37.
190. Hasegawa T., Juni K., Saneyoshi M., Kawaguchi T. Intestinal absorption and first-pass elimination of 2′, 3′-dideoxynucleosides following oral administration in rats. Biol. Pharm. Bull. 19:1996;599-603.
191. Kawaguchi T., Hasegawa T., Seki T., Juni K., Morimoto Y., Miyakawa A., Saneyoshi M. Prodrugs of 2′,3′-dideoxyinosine (DDI): improved oral bioavailability via hydrophobic esters. Chem. Pharm. Bull. 40:1992;1338-1340.
192. Anderson B.D., Galinsky R.E., Baker D.C., Chi S.C., Mitsuya H., et al. Approaches toward the optimization of CNS uptake of anti-AIDS agents. J. Controlled Rel. 19:1992;219-229.
193. Little R.D., Bailey D., Brewster M., Estes K., Clemmons A., Saab A., Bodor N. Improved delivery through biological membranes. XXXIII. Brain-enhanced levels of zidovudine (AZT). J. Biopharm. Sci. 1:1990;1-18.
194. Torrence P.F., Kinjo J., Khamnei S., Greig N.H. Synthesis and pharmacokinetics of a dihydropyridine chemical delivery system for the antiimmunodeficiency virus agent dideoxycytidine. J. Med. Chem. 36:1993;529-537.
195. Chu C.K., Ullas G.V., Jeong L.S., Ahn S.K., Doboszewski B., Lin Z.X., Beach J.W., Schinazi R.F. Synthesis and structure-activity relationships of 6-substituted 2′,3′-dideoxypurine nucleosides as potential anti-human immunodeficiency virus agents. J. Med. Chem. 33:1990;1553-1561.
196. Namane A., Gouyette C., Fillion M.P., Fillion G., Huynh D.T. Improved brain delivery of AZT using a glycosyl phosphotriester prodrug. J. Med. Chem. 35:1992;3039-3044.
197. Mizrachi Y., Rubinstein A., Harish Z., Biegon A., Anderson W.R., Brewster M.E. Improved brain delivery and in vitro activity of zidovudine through the use of a redox chemical delivery system. AIDS. 9:1995;153-158.
198. Brewster M.E., Anderson W.R., Helton D.O., Bodor N., Pop E. Dose-dependent brain delivery of zidovudine through the use of a zidovudine chemical delivery system. Pharm. Res. 12:1995;796-798.
199. Brewster M.E., Anderson W.R., Webb A.I., Pablo L.M., Meinsma D., Moreno D., Derendorf H., Bodor N., Pop E. Evaluation of a brain-targeting zidovudine chemical delivery system in dogs. Antimicrob. Agents Chemother. 41:1997;122-128.
200. Chu C.K., Bhadti V.S., Doshi K.J., Etse J.T., Gallo J.M., Boudinot F.D., Schinazi R.F. Brain targeting of anti-HIV nucleosides: synthesis and in vitro and in vivo studies of dihydropyridine derivatives of 3′-azido-2′,3′-dideoxyuridine and 3′-azido-3′-deoxythymidine. J. Med. Chem. 33:1990;2188-2192.
201. Shirasaka T., Murakami K., Ford H. Jr., Kelley J.A., Yoshioka H., Kojima E., Aoki S., Broder S., Mitsuya H. Lipophilic halogenated congeners of 2′,3′-dideoxypurine nucleosides active against human immunodeficiency virus in vitro. Proc. Natl. Acad. Sci. USA. 87:1990;9426-9430.
202. Singhal D., Anderson B.D. Optimization of the local inhibition of intestinal adenosine deaminase (ADA) by erythro-9-(2-hydroxy-3-nonyl)adenine: enhanced oral delivery of an ADA-activated prodrug for anti-HIV therapy. J. Pharm. Sci. 87:1998;578-585.
203. Desormeaux A., Harvie P., Perron S., Makabi P.B., Beauchamp D., Tremblay M., Poulin L., Bergeron M.G. Antiviral efficacy, intracellular uptake and pharmacokinetics of free and liposome-encapsulated 2′,3′-dideoxyinosine. AIDS. 8:1994;1545-1553.
204. Harvie P., Desormeaux A., Gagne N., Tremblay M., Poulin L., Beauchamp D., Bergeron M.G. Lymphoid tissues targeting of liposome-encapsulated 2′,3′-dideoxyinosine. AIDS. 9:1995;701-707.
205. Dipali S.R., Lin Y.J., Ravis W.R., Betageri G.V. Pharmacokinetics and tissue distribution of a long circulating liposomal formulation of 2′,3′-dideoxyinosine. Int. J. Pharm. 152:1997;89-97.
206. Betageri G.V., Black C.D., Szebeni J., Wahl L.M., Weinstein J.N. Fc-receptor-mediated targeting of antibody-bearing liposomes containing dideoxycytidine triphosphate to human monocyte/macrophages. J. Pharm. Pharmacol. 45:1993;48-53.
207. Molema G., Jansen R.W., Pauwels R., de C.E., Meijer D.K. Targeting of antiviral drugs to T4-lymphocytes. Anti-HIV activity of neoglycoprotein-AZTMP conjugates in vitro. Biochem. Pharmacol. 40:1990;2603-2610.
208. Bibby D.C., Charman W.N., Charman S.A., Iskander M.N., Porter C.J. Synthesis and evaluation of 5′ alkyl ester prodrugs of zidovudine for directed lymphatic delivery. Int. J. Pharm. 144:1996;61-70.
209. Bender A., Schfer V., Steffan A.M., Royer C., Kreuter J., Rubsamen W.H., von B.H. Inhibition of HIV in vitro by antiviral drug-targeting using nanoparticles. Res. Virol. 145:1994;215-220.
210. Bender A.R., von B.H., Kreuter J., Duncan I.B., Rubsamen W.H. Efficiency of nanoparticles as a carrier system for antiviral agents in human immunodeficiency virus-infected human monocytes/macrophages in vitro. Antimicrob. Agents Chemother. 40:1996;1467-1471.
211. Kawaguchi T., Ishikawa K., Seki T., Juni K. Ester prodrugs of zidovudine. J. Pharm. Sci. 79:1990;531-533.
212. Aggarwal S.K., Gogu S.R., Rangan S.R., Agrawal K.C. Synthesis and biological evaluation of prodrugs of zidovudine. J. Med. Chem. 33:1990;1505-1510.
213. Hasegawa T., Seki T., Juni K., Saneyoshi M., Kawaguchi T. Prodrugs of 2′,3′-didehydro-3′-deoxythymidine. J. Pharm. Sci. 82:1993;1232-1236.
214. Tortolani D.R., Russell J.W., Whiterock V.J., Hitchcock M.J., Ghazzouli I., Martin J.C., Mansuri M.M., Starrett J.J. Prodrugs of 2′,3′-didehydro-3′-deoxythymidine (D4T): synthesis, antiviral activity, and rapid pharmacokinetic evaluation. J. Pharm. Sci. 83:1994;339-343.
215. Abu-Izza K.A., Garcia C.L., Lu D.R. Preparation and evaluation of sustained release AZT-loaded microspheres: optimization of the release characteristics using response surface methodology. J. Pharm. Sci. 85:1996;144-149.
216. Magnani M., Bianchi M., Rossi L., Stocchi V. Human red blood cells as bioreactors for the release of 2′,3′-dideoxycytidine, an inhibitor of HIV infectivity. Biochem. Biophys. Res. Commun. 164:1989;446-452.
217. Klecker R.W.J., Collins J.M., Yarchoan R., Thomas R., Jenkins J.F., Broder S., Myers C.E. Plasma and cerebrospinal fluid pharmacokinetics of 3′-azido-3′-deoxythymidine: a novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases. Clin. Pharmacol. Ther. 41:1987;407-412.
218. Lea A.P., Faulds D. Stavudine: a review of its pharmacodynamic and pharmacokinetic properties and clinical potential in HIV infection. Drugs. 51:1996;846-864.
219. Hayden F.G. Antimicrobial agents. Hardman J.G., et al. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 1996;1191-1223 McGraw-Hill, New York.
220. Yuen G.J., Morris D.M., Mydlow P.K., Haidar S., Hall S.T., Hussey E.K. Pharmacokinetics, absolute bioavailability, and absorption characteristics of lamivudine. J. Clin. Pharmacol. 35:1995;1174-1180. [published erratum appears in J. Clin. Pharmacol. 36(4) (1996 Apr) 373].
221. Noble S., Faulds D. Saquinavir. A review of its pharmacology and clinical potential in the management of HIV infection. Drugs. 52:1996;93-112.
222. Vella S., Floridia M. Saquinavir. Clinical pharmacology and efficacy. Clin. Pharmacokinet. 34:1998;189-201.
223. Perry C.M., Benfield P. Nelfinavir. Drugs. 54:1997;81-87.
224. Voorman R.L., Maio S.M., Hauer M.J., Sanders P.E., Payne N.A., Ackland M.J. Metabolism of delavirdine, a human immunodeficiency virus type-1 reverse transcriptase inhibitor, by microsomal cytochrome P450 in humans, rats, and other species: probable involvement of CYP2D6 and CYP3A. Drug Metab. Dispos. 26:1998;631-639.
225. Morse G.D., Fischl M.A., Shelton M.J., Cox S.R., Driver M., DeRemer M., Freimuth W.W. Single-dose pharmacokinetics of delavirdine mesylate and didanosine in patients with human immunodeficiency virus infection. Antimicrob. Agents Chemother. 41:1997;169-174.